Valuation: Alkem Laboratories Limited

Market Cap 646B 6.75B 5.78B 5.39B 4.95B 9.29B 9.48B 63.95B 24.93B 324B 25.34B 24.78B 1,071B P/E 2027 *
28.1x
P/E 2028 * 24.5x
Enterprise Value 633B 6.61B 5.66B 5.28B 4.85B 9.11B 9.29B 62.65B 24.42B 317B 24.82B 24.28B 1,050B EV / Sales 2027 *
3.79x
EV / Sales 2028 * 3.33x
Free-Float
37.56%
Yield 2027 *
0.91%
Yield 2028 * 1.02%
1 day+0.33%
1 week-0.91%
Current month-6.11%
1 month-4.48%
3 months-0.67%
6 months+0.15%
Current year-1.93%
1 week 5,312
Extreme 5312
5,510
1 month 5,175
Extreme 5175
5,882.5
Current year 5,075
Extreme 5075
5,933.5
1 year 5,075
Extreme 5075
5,933.5
3 years 3,447
Extreme 3447
6,439.9
5 years 2,828
Extreme 2828
6,439.9
10 years 1,455
Extreme 1455
6,439.9
Manager TitleAgeSince
President - -
President - -
Director of Finance/CFO - 31/01/2024
Director TitleAgeSince
Director/Board Member 44 08/08/2013
Director/Board Member 63 10/02/2008
Director/Board Member 45 10/11/2019
Change 5-day change 1-year change 3-year change Capi.($)
+0.33%-0.91%+0.13%+42.06% 6.73B
-2.81%+2.93%+76.40%+127.73% 1,141B
-2.21%+2.02%+49.50%+55.01% 659B
-1.56%+4.39%+25.19%+74.39% 470B
+1.20%+2.62%+41.69%+45.78% 366B
-0.61%+2.10%+23.43%+41.34% 302B
+0.32%+3.25%+0.94%+13.42% 254B
-1.95%+3.80%+46.31%+65.66% 239B
-1.10%-0.70%-14.31%-52.66% 207B
-2.82%+3.84%+20.81%+89.04% 183B
Average -1.12%+2.41%+27.01%+50.17% 382.77B
Weighted average by Cap. -1.64%+3.11%+43.41%+70.81%

Financials

2027 *2028 *
Net sales 167B 1.75B 1.49B 1.39B 1.28B 2.4B 2.45B 16.54B 6.45B 83.69B 6.55B 6.41B 277B 186B 1.94B 1.66B 1.55B 1.42B 2.67B 2.73B 18.39B 7.17B 93.08B 7.29B 7.13B 308B
Net income 23.14B 242M 207M 193M 177M 333M 340M 2.29B 894M 11.6B 908M 888M 38.4B 27.15B 284M 243M 227M 208M 391M 399M 2.69B 1.05B 13.61B 1.07B 1.04B 45.05B
Net Debt -13.08B -137M -117M -109M -100M -188M -192M -1.3B -505M -6.55B -513M -502M -21.7B -28.06B -293M -251M -234M -215M -404M -412M -2.78B -1.08B -14.06B -1.1B -1.08B -46.55B
Logo Alkem Laboratories Limited
Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.
Employees
19,346
Date Price Change Volume
20/08/26 ₹5,400.00 +0.33% 85,369
19/08/26 ₹5,382.50 -1.69% 213,076
18/08/26 ₹5,475.00 +1.88% 127,028
17/08/26 ₹5,374.00 +0.11% 153,275
14/08/26 ₹5,368.00 -1.50% 635,598
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
5,400.00INR
Average target price
5,948.55INR
Spread / Average Target
+10.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKEM Stock